Equillium, Inc.

EQ ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $-4.7M $-5.3M $-3.8M $-4.2M $-5.7M $-8.7M $-5.8M $-7.0K
Depreciation & Amortization — — — — — — — —
Depreciation $26.0K $24.0K $23.0K $28.0K $32.0K $33.0K $35.0K $35.0K
Amortization — — — — — — — —
Stock-Based Compensation $1.1M $930.0K $737.0K $401.0K $563.0K $621.0K $821.0K $1.0M
Net Cash from Operating Activities $-4.1M $-4.3M $-3.1M $-8.4M $-3.0M $-8.2M $-3.3M $-7.7M
Investing Activities
Capital Expenditures $71.0K $3.0K $44.0K $0 $0 $4.0K $4.0K $0
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-71.0K $-3.0K $-32.0K $0 $0 $4.5M $6.0M $12.0M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $42.0K $35.3M $283.0K $30.1M $-16.0K $91.0K — —
Net Change in Cash $-4.2M $31.0M $-2.8M $21.6M $-3.0M $-3.6M $2.6M $4.4M
Free Cash Flow $-4.2M $-4.3M $-3.2M $-8.4M $-3.0M $-8.2M $-3.3M $-7.7M
← Newer Page 1 of 5 Older →